Evidence map›Paper›PMID 41859348›Full record

ArticleBlood neoplasia2026

Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.

Luis E Aguirre, Jan Philipp Bewersdorf, Yiwen Liu, Rory M Shallis, Leora Boussi, Andrius Zucenka, Sylvain Garciaz, Rebecca P Bystrom, Daniel J DeAngelo, Richard M Stone and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Luis E AguirreDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Jan Philipp BewersdorfSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Yiwen LiuDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA.
Rory M ShallisDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Leora BoussiMemorial Sloan Kettering Cancer Center, New York, NY.
Andrius ZucenkaDepartment of Hematology and Oncology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Sylvain GarciazCentre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Aix-Marseille Université, INSERM, Centre National de la Recherche Scientifique, Marseille, France.
Rebecca P BystromDivision of Hematologic Malignancies and Cellular Therapy, Duke Blood Cancer Center, Durham, NC.
Daniel J DeAngeloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Richard M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Marlise R LuskinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Jacqueline S GarciaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Eric S WinerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Kelly LingSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Evan C ChenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Martha WadleighDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Guillaume BertonCentre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Aix-Marseille Université, INSERM, Centre National de la Recherche Scientifique, Marseille, France.
Eytan M SteinMemorial Sloan Kettering Cancer Center, New York, NY.
Aaron D GoldbergMemorial Sloan Kettering Cancer Center, New York, NY.
Lourdes MendezSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Amer M ZeidanSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
David A SallmanDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Shai ShimonyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Maximilian StahlDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

The optimal frontline therapy for acute myeloid leukemia (AML) with very high-risk cytogenetics (vHRC)-defined by complex karyotype (CK), monosomal karyotype (MK), or inv(3)/t(3;3)-remains uncertain. We retrospectively analyzed 358 newly diagnosed AML-vHRC cases treated at five academic centers (2014-2024), stratified by intensive chemotherapy (IC) vs hypomethylating agent plus venetoclax (HMA+ven). Cytogenetic features included CK in 90.2%, MK in 64%, and inv(3)/t(3;3) in 9.8%;

Identifiers

PMID41859348
PMCPMC12997325

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.